Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
substance use disorder
Biotech
Indivior expects 'significant' R&D team impact after ph. 2 fail
Indivior ended internal development of an opioid use disorder candidate after a phase 2 trial missed its primary endpoint.
Nick Paul Taylor
Apr 30, 2026 9:43am
AI model designs new treatment candidate for opioid addiction
Apr 6, 2026 3:00pm
Addex stock rises after Indivior offers up to $300M for compound
Aug 27, 2024 10:50am
Click, Indivior to make digital therapeutics for addiction
Sep 8, 2023 1:13pm
C4X sells substance disorder drug rights to Indivior for $20M
Aug 1, 2023 7:49am
Prescription app maker Pear Therapeutics files for bankruptcy
Apr 10, 2023 10:13am
